Galapagos N.V. | Balance Sheet

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
138
198
356
980
1,151
1,291
Total Accounts Receivable
32
14
16
23
42
34
Inventories
-
-
-
-
-
-
Other Current Assets
-
-
-
2
1
-
Total Current Assets
173
212
372
1,004
1,194
1,325
Net Property, Plant & Equipment
20
10
14
15
17
23
Total Investments and Advances
-
3
1
3
3
7
Long-Term Note Receivable
39
44
49
54
64
73
Intangible Assets
47
2
2
1
2
4
Other Assets
1
2
3
4
4
5
Total Assets
287
270
443
1,083
1,286
1,439
ST Debt & Current Portion LT Debt
-
-
-
-
-
Accounts Payable
29
29
29
31
47
Income Tax Payable
-
3
3
1
1
Other Current Liabilities
83
28
41
72
124
Total Current Liabilities
113
60
72
104
172
Long-Term Debt
-
-
-
-
-
Provision for Risks & Charges
3
3
3
4
4
Deferred Taxes
2
-
2
2
2
Other Liabilities
2
1
2
217
99
Total Liabilities
120
64
78
325
274
Common Equity (Total)
167
206
365
759
1,012
Total Shareholders' Equity
167
206
365
759
1,012
Total Equity
167
206
365
759
1,012
Liabilities & Shareholders' Equity
287
270
443
1,083
1,286

About Galapagos

View Profile
Address
Industriepark Mechelen Noord
Mechelen BU 2800
Belgium
Employees -
Website http://www.glpg.com
Updated 07/08/2019
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.